Literature DB >> 2843782

Anticonvulsant and antiepileptogenic actions of MK-801 in the kindling and electroshock models.

J O McNamara1, R D Russell, L Rigsbee, D W Bonhaus.   

Abstract

The actions of MK-801, a noncompetitive antagonist at the N-methyl-d-aspartate subtype of excitatory amino acid receptor, were investigated on the development of kindling and on seizures in the electroshock and kindling models. The drug MK-801 potently and effectively suppressed the tonic hindlimb extension component of electroshock-induced seizures; it also suppressed both the electrophysiological and behavioral manifestations of the development of kindling. In contrast to its effects on electroshock-induced seizures and the development of kindling, MK-801 only partly reduced the duration of seizures in fully kindled animals and did not elevate the threshold for afterdischarge despite the use of a large dose, associated with profound untoward behavioral effects. Together with previous findings, these results support the idea that noncompetitive blockade of NMDA receptors markedly inhibits the development of kindling. The diminished effectiveness of MK-801 against kindled seizures suggests that MK-801 will not be a clinically-useful anticonvulsant against complex partial seizures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2843782     DOI: 10.1016/0028-3908(88)90176-1

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  37 in total

1.  Effects of electroconvulsive stimuli and MK-801 on neuropeptide Y, neurokinin A, and calcitonin gene-related peptide in rat brain.

Authors:  A A Mathé; S Gruber; P A Jiménez; E Theodorsson; C Stenfors
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

2.  MK-801 prevents the enhanced behavioural response to apomorphine elicited by repeated electroconvulsive treatment in mice.

Authors:  G G Nomikos; A A Mathé; J M Mathé; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Chronic administration of valproic acid induces a decrease in rat striatal glutamate and taurine levels.

Authors:  G B Acosta; S I Wikinski; C C Bonelli; M C Rubio
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

4.  Long-term D1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist.

Authors:  H E Criswell; R A Mueller; G R Breese
Journal:  Brain Res       Date:  1990-04-02       Impact factor: 3.252

5.  NMDA receptor dependence of kindling and mossy fiber sprouting: evidence that the NMDA receptor regulates patterning of hippocampal circuits in the adult brain.

Authors:  T Sutula; J Koch; G Golarai; Y Watanabe; J O McNamara
Journal:  J Neurosci       Date:  1996-11-15       Impact factor: 6.167

6.  The effect of MK-801 and other antagonists of NMDA-type glutamate receptors on brain-stimulation reward.

Authors:  L J Herberg; I C Rose
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat.

Authors:  R Dall'Olio; O Gandolfi
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats.

Authors:  W Löscher; P Wlaź; C Rundfeldt; H Baran; D Hönack
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  Behavioral studies on FR115427, a novel selective N-methyl-D-aspartate antagonist.

Authors:  H Nakanishi; K Katsuta; Y Ueda; H Takasugi; A Kuno; M Ohkubo; K Ogita; Y Yoneda; K Shirakawa; K Yoshida
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

10.  Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats.

Authors:  Ajay K Srivastava; H Steve White
Journal:  Epilepsy Res       Date:  2012-11-14       Impact factor: 3.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.